

AMR INDUSTRY ALLIANCE

2025 Year In Review





Table of Contents



Letter from the Chair	4
AMR Industry Alliance Members	5
Introduction	8
2025 Timeline of Key Milestones	9

Alliance Focus Areas



Access

Principles for Pooled Procurement of AMR Products	14
---	----

Appropriate Use

2025 Stewardship Prize	17
------------------------	----

Manufacturing



Updated Antibiotic Manufacturing Standard	20
---	----

BSI Certification	20
-------------------	----

Certification milestone: 100 products independently certified by BSI to AMRIA standard	20
--	----

Research & Science

Report: The Faltering Antibiotic Pipeline	23
---	----



AMR Industry Alliance's Global Engagement	24
---	----

AMRIA in the Press	27
--------------------	----

Looking Ahead	29
---------------	----

References	31
------------	----

Letter from the Chair

2025 was a year that underscored both the scale of the antimicrobial resistance (AMR) challenge and the critical importance of sustained, coordinated action. As the international community works to translate the commitments made at the 2024 United Nations High-Level Meeting on AMR into meaningful action, the AMR Industry Alliance has continued to play a central role in driving practical, solutions-oriented engagement across sectors.

AMR remains one of the most urgent threats to global health, economic stability, and modern medicine. Yet in 2025, meaningful progress showed that collective action can make a difference. When industry, governments, and international organizations work together with a shared sense of responsibility, important momentum was sustained. Throughout the year, the Alliance strengthened its role as a trusted private-sector partner by convening stakeholders, contributing technical expertise, and advancing practical initiatives that helped turn commitment into implementation.

A defining feature of 2025 was the Alliance's continued leadership in responsible antibiotic manufacturing. Building on the foundation established in prior years, the revised Antibiotic Manufacturing Standard and the expansion of independent BSI certifications marked a significant milestone, with more than 100 antibiotic products now certified across global supply chains. This progress reflects a shared commitment by Alliance members to mitigate environmental risks associated with antibiotic manufacturing and to demonstrate that high standards, transparency, and accountability are achievable at scale.

Global engagement remained a cornerstone of the Alliance's efforts in 2025. Through continued collaboration with the World Health Organization, Africa CDC, and the AMR Multi-Stakeholder Partnership Platform, the Alliance advanced dialogues on access, stewardship, innovation, and governance.

As this report illustrates, the Alliance's work spans manufacturing, stewardship, access, advocacy, and innovation. What unites these efforts is a clear and enduring purpose: to safeguard the effectiveness of antimicrobials and preserve the foundations of modern medicine. We do this through partnership, evidence, and action—recognizing that no single sector can address AMR alone.

Looking ahead, the challenge of AMR demands sustained leadership, investment, and deeper collaboration across the public and private sectors. I hope this report serves not only as a record of progress, but also as a catalyst for renewed commitment and collective action in the year to come.


James Anderson, Chair, AMR Industry Alliance

AMR Industry Alliance Members









Introduction

Antimicrobial resistance (AMR) poses a critical global health threat, and will continue to escalate without concerted, coordinated action. Recent projections indicate that between 2025 and 2030, AMR could directly cause 39 million deaths worldwide, equating to approximately three deaths every minute.¹ If current trends persist, annual deaths directly attributable to AMR are expected to rise from 1.14 million in 2021 to 1.91 million by 2050.²

Beyond its profound human toll, AMR also poses a significant economic threat. Direct healthcare costs associated with AMR are projected to increase from \$66 billion annually to \$159 billion by 2050.³ At the same time, the global economy could suffer losses up to \$1.7 trillion per year due to reduced labor force participation and productivity.⁴

Building on the momentum of the 2024 United Nations High-Level Meeting on AMR, 2025 marked a transition from global commitment to practical implementation. As the largest life-sciences coalition of its kind, the AMR Industry Alliance continued to serve as a key private-sector partner, convening stakeholders across government, industry, and NGOs working in human, animal, and agricultural health to drive coordinated action and advance evidence-based solutions.

Global engagement remained central to the Alliance's mission. Through continued collaboration with the World Health Organization, Africa CDC, the AMR Multi-Stakeholder Partnership Platform, and several other partners, the Alliance contributed expertise to global discussions on access, stewardship, manufacturing, and innovation. These engagements reflect a shared understanding that addressing AMR requires sustained cooperation across public and private sectors, from governments, industry, academia, and civil society, for a concerted One Health approach. The urgency to act against AMR is clear. Without immediate and coordinated efforts, we risk undermining a century of medical advancements and facing a future where common infections become untreatable.

2025 AMR Industry Alliance Timeline of Key Milestones

EVENTS

PUBLICATIONS

MANUFACTURING INITIATIVES

JANUARY

FEBRUARY

- Wilton Park Meeting: "Reinvigorating the response to antimicrobial resistance (AMR): from aspiration to implementation"

MARCH

APRIL

MAY

- *Revised Antibiotic Manufacturing Standard: Minimizing risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from the manufacturing of human antibiotics*

JUNE

JULY

AUGUST

SEPTEMBER

- 2025 Annual AMR Masterclass

OCTOBER

- *Principles for Pooled Procurement of AMR Products*

- Africa CDC Continental Stakeholders Meeting on Access to Antimicrobials, Diagnostics, and Vaccines as Countermeasures to AMR

NOVEMBER

- WAAW Webinar: "Building Cross-Sectoral Coalitions for Urgent Action on AMR"
- 2025 Stewardship Prize Winner announced

DECEMBER

- Manufacturing certification landmark: 100 antibiotic products independently certified through BSI Kitemark to the AMRIA Antibiotic Manufacturing Standard
- *The Faltering Antibiotic Pipeline*

A close-up photograph of a microscope lens, showing the lens barrel with technical markings like 'M', '9', and '1.2'. The lens is illuminated from below, creating a warm glow. The background is a soft, out-of-focus blue.

ALLIANCE FOCUS AREAS

Alliance Focus Areas

The AMR Industry Alliance focuses its work in four key areas: Access, Appropriate Use, Manufacturing, and Research and Science. In convening leaders across the life sciences industry, the Alliance works collaboratively to advance the dialogue on AMR and foster sustainable solutions centered on engagement, advocacy, and action.

Along with its traditional focus areas, the Alliance expanded its activities to include advocacy in 2024.

ALLIANCE FOCUS AREAS

2025 ALLIANCE HIGHLIGHTS

ACCESS

Access to quality antibiotics and ensuring novel antibiotics are available to all, and improve and amplify access to diagnostics in low-and middle-income countries

Principles for Pooled Procurement

APPROPRIATE USE

Appropriate use of antibiotics to curb the development of AMR

2025 AMR Stewardship Prize

MANUFACTURING

Manufacturing to mitigate the environmental impact and drive responsible manufacturing through standards

BSI Certification
Revised Antibiotic Manufacturing Standard

RESEARCH & SCIENCE

Research and science to achieve public health needs with novel innovative diagnostics and treatments

The Faltering Antibiotic Pipeline

ADVOCACY

Advocacy to engage diverse stakeholders to advance policy to support the key pillars

Wilton Park Series
WHO and Africa CDC Engagement
Co-facilitated the Independent Scientific Panel and GAP Hearings through MSPP



Access

Working to remove
barriers to equitable
access to antibiotics
around the world

2025 ALLIANCE ACCESS HIGHLIGHTS:



Principles for Pooled Procurement of AMR Products

To curb the spread of antimicrobial resistance, it is essential to ensure access to the right antimicrobials and diagnostic tools to save lives. Without timely diagnostics and appropriate treatments, clinicians may be forced to rely on suboptimal or broad-spectrum therapies that fail to appropriately treat or fully eliminate pathogens. This can lead to poorer patient outcomes and accelerate the development and spread of antimicrobial resistance.

Access to essential antimicrobials remains a significant global challenge. Research shows that in many low- and middle-income countries, nearly half of healthcare facilities lack access to these critical medicines.⁵ At the same time, access challenges are not confined to these settings—high-income countries also face barriers, including fragile supply chains and lack of drug approvals—with some countries approving as few as two novel antimicrobials in the past decade.^{6,7}

The AMR Industry Alliance is dedicated to improving global access to antimicrobials and advancing diagnostic capabilities. Through both individual and collaborative initiatives, Alliance members are working to address the root causes of access challenges in low-, middle-, and high-income countries.



AMR Industry Alliance Commitments in Access

Address barriers to patient access to the most appropriate treatment, vaccine or diagnostic.

Work in collaboration with policymakers to create an economic and regulatory environment that enable the sustainable supply of quality-assured antibiotics.

Work to reduce the prevalence of substandard and falsified AMR-relevant products.

Principles for Pooled Procurement of AMR Products

The AMR Industry Alliance Principles for Pooled Procurement of AMR Products aims to support purchasers in low- and lower-middle-income countries (LMICs) in establishing pooled procurement mechanisms (PPMs) for antimicrobial resistance products, including antibiotics and diagnostics. The document makes nine recommendations:



- 1 Provide accurate demand forecasting and clear, transparent tender calendars.
- 2 Ensure rational and appropriate use of antibiotics supported by robust stewardship programs.
- 3 Increase transparency in decision-making and tender awarding.
- 4 Establish clear criteria and guidelines for country pooling.
- 5 Create or utilize an appropriate structure to ensure the success of small volume tenders.
- 6 Ensure accountability measures to govern technical and financial capacities.
- 7 Allow non-exclusive, voluntary participation with flexible procurement options.
- 8 Regulatory harmonization and reliance-based regulatory practices.
- 9 Mobilize sustainable funding streams for high-quality products in cases where donor funding is needed.

These principles highlight the key role that private sector participation can play in ensuring availability, reliability, and sustainability of supply across AMR products, especially in settings with regulatory issues, inadequate demand forecasting, unsustainable procurement practices, and lack of market incentives.

Pooled procurement is a key mechanism for addressing the broader market failures affecting the AMR ecosystem. However, market models that recognize the full value of antibiotics and diagnostics, regulatory harmonization, and stewardship are also essential.

Initial discussions on the Pooled Procurement Principles took place during the World Health Assembly in May, and the finalized document was launched ahead of the Africa CDC meeting in October.



Appropriate Use

Promoting awareness and
stewardship in the use of
antibiotics

2025 ALLIANCE APPROPRIATE USE HIGHLIGHTS:



2025 Stewardship Prize

The inappropriate use of antimicrobials poses a critical global threat—endangering lives, prolonging patient recovery, and accelerating the spread of antimicrobial resistance (AMR). When antimicrobials are used appropriately, they effectively reduce the number of pathogens capable of developing resistance, thereby preserving the efficacy of commonly used treatments. Conversely, misuse or overuse accelerate the emergence of resistant pathogens, diminishing treatment options and placing public health at risk.

Research shows that at least 50% of antimicrobial prescriptions worldwide are either unnecessary or inappropriate, highlighting a significant opportunity for improvement.⁸ Addressing this challenge requires a multifaceted approach, including greater adoption of diagnostic testing by healthcare professionals to ensure timely and targeted treatment decisions. In parallel, strengthening the use of surveillance data is essential to increase awareness of AMR trends and support the implementation of effective antimicrobial stewardship programs.

Approximately 80% of Alliance members are actively implementing stewardship strategies, ensuring the responsible use of antimicrobials remains a top priority. The AMR Industry Alliance is committed to advance initiatives that promote appropriate use, working in collaboration with external partners to raise awareness, enhance surveillance systems, and expand the use of diagnostics.

AMR Industry Alliance Commitments in Appropriate Use

Contribute to slowing emergent resistance by preventing infections through vaccination promotion and reducing the inappropriate use of antibiotics via the expanded use of diagnostics.

Support the appropriate use of antibiotics by working closely with other partners on awareness campaigns, continued education for healthcare professionals and generation of evidence to support appropriate use and stewardship.

Collect and share surveillance data with public health bodies and healthcare professionals to improve understanding of resistance trends, monitor the effectiveness of antibiotics, inform appropriate antibiotic and vaccine use and develop adapted infection control strategies.

Ensure that any promotional activities for antibiotics align with the goal of advancing stewardship.

Stewardship Prize

Since its establishment in 2021, the Alliance’s annual Stewardship Prize has recognized programs that demonstrate innovative, scalable approaches to advancing antimicrobial stewardship in low- and middle-income countries. This prize includes a monetary grant to support the expansion and sustainability of these efforts. In 2025, the prize was awarded to Impala Healthtech Research Limited’s Digital Antimicrobial Stewardship System (DIGAMS) in Uganda.



DIGAMS is a digital, community-integrated, AI-enabled antimicrobial stewardship system designed to extend access to microbiology diagnostic testing in under-resourced settings. The system supports evidence-based antimicrobial use by guiding empirical treatment decisions through integrated resistance and treatment data, while also strengthening stewardship practices. The platform combines a modular laboratory and health management information system with a stewardship assessment tool, as well as sample referral and tracking capabilities. It also includes a search function that enables users to filter by location, pricing, turnaround time, and user feedback—enhancing accessibility and usability for healthcare providers.

DIGAMS has been implemented in 199 small healthcare facilities, used by 142 professionals, and served over 2000 patients.

PILOT PROGRAM RESULTS



59% reduction in inappropriate Rx



27% reduction in hospital stay durations



32% reduction in treatment optimization time



Impala Healthtech Research Limited was announced the winner during the World AMR Awareness Week 2025 webinar, “Building Cross-Sectoral Coalitions for Urgent Action on AMR.”



Manufacturing

Setting the standard for
mitigating the environmental
effects of AMR

2025 ALLIANCE MANUFACTURING HIGHLIGHTS:



Revised Antibiotic Manufacturing Standard

BSI Certification

Globally, the discharge of active pharmaceutical ingredients (APIs) from manufacturing facilities is not regulated. The Alliance is leading the way in setting and promoting targets for responsible manufacturing.

While the primary source of pharmaceuticals in the environment remains the use and subsequent excretion of medicines by patients, emissions of antibiotics from manufacturing sites can contribute to the development of antimicrobial resistance (AMR). This risk arises when antibiotic concentrations in wastewater exceed levels that may create selective pressure, encouraging bacteria to develop resistance.

To address this, all manufacturing members of the Alliance have committed to aligning with the Antibiotic Manufacturing Standard, including adherence to the Predicted No-Effect Concentrations (PNECs). Working to meet this standard is a condition of Alliance membership and reflects a shared commitment to mitigating AMR risks in the environment.

Since its inception in 2017, the AMR Industry Alliance has led the way in developing, implementing, and upholding responsible environmental practices in antibiotic manufacturing, reinforcing the Industry's role in the global fight against AMR.

AMR Industry Alliance Commitments in Manufacturing

Review Alliance member's own manufacturing and supply chains to assess good practices in controlling the release of antibiotics into the environment.


Establish a common framework for managing antibiotic discharge and start applying it across their own manufacturing and supply chains; continue to implement the framework in the following years to reduce environmental risk due to manufacturing discharges.

Work with independent technical experts to establish science-driven, risk-based targets for discharge concentrations of antibiotics, develop good-practice methods to reduce environmental impacts of manufacturing discharges and work with members to ensure that discharge targets are met.

Work with stakeholders to develop a practical mechanism to transparently show that Alliance members' supply chains meet the framework's standards.

Antibiotic Manufacturing Standard

The AMR Industry Alliance updated its Antibiotic Manufacturing Standard to reflect two years of implementation experience, incorporate the World Health Organization's 2024 guidance on controlling emissions from antibiotic production, and integrate the latest science informing AMRIA's antibiotic predicted no-effect concentrations (PNECs). The standard provides clear guidance to manufacturers in the global antibiotic supply chain to ensure that their antibiotics are made responsibly, helping to minimize the risk of AMR in the environment. The Alliance continues collaborating with associations to monitor and shape the evolving AMR environmental science and regulatory landscape.



BSI Certification



The AMR Industry Alliance Standard is the only independently certifiable standard for responsible antibiotic manufacturing. Since 2023, BSI has operated a certification program that conducts third-party assessments and verifies conformance with the Alliance's standard, helping build transparency and trust across the supply chain. BSI will incorporate the revised Antibiotic Manufacturing Standard into its AMR certification program in early 2026.

Certification Milestone: 100+ Products Certified to Alliance's Manufacturing Standard

Launched in 2023, the BSI Kitemark™ for Minimized Risk of AMR Certification™ validates compliance with the AMR Industry Alliance's Responsible Manufacturing Standard, ensuring antibiotic residue emissions from waste streams are controlled during manufacturing and meet Predicted No Effect Concentration (PNEC) thresholds. In 2025, the Alliance advances certification across its members' supply chains, reaching 100 certificates from more than 20 different countries by the end of the year.

2025 Annual AMR Masterclass

During the 2025 Annual AMR Masterclass, BSI and the Chair of the Manufacturing Working Group highlighted the Alliance's efforts to drive adoption of the industry standard and expanded BSI certification across the global antibiotic supply chain.



Research & Science

Addressing barriers to
innovation

2025 ALLIANCE RESEARCH & SCIENCE HIGHLIGHTS:



The Faltering Antibiotic Pipeline

The research and development landscape for new antimicrobials has experienced a marked and concerning decline. Between 1950 and 2000, the US FDA approved an average of 23 new antimicrobials per decade. Since 2000, this figure has dropped to a remarkable 14 per decade.⁹ Of 53 antibiotics approved by the FDA over the past 30 years, only one has represented a novel compound with direct action against a previously unaddressed bacterial target.¹⁰

The decline stands in stark contrast to the growing global threat of antimicrobial resistance (AMR), underscoring the urgent need to renew focus on antimicrobial research and development. Through sustained investment by its members and the work of the Research and Science Working Group, the Alliance supports clinical initiatives. These include publications such as *Leaving the Lab: Tracking the Decline in AMR R&D Professionals* and *The Faltering Antibiotic Pipeline*, which highlight the shrinking pool of scientific expertise and the broader challenges facing antimicrobial development.

Since its establishment, the Alliance has remained committed to identifying systemic barriers within the antimicrobial marketplace and advocating for viable, long-term solutions. Its efforts span policy advocacy to incentivize innovation, support for collaborative frameworks and data-sharing initiatives, and original research to assess current regulatory environments and advance targeted, evidence-based improvements.

AMR Industry Alliance Commitments in Manufacturing

Invest in research and development for innovative antibiotics and dosage forms, vaccines, new technologies, and diagnostics.

Continue to advocate for policies that support sustainable investment in AMR-relevant innovations.

Partner with policymakers, payers, and other relevant stakeholders on new reimbursement, valuation and commercial models that support appropriate patient access and a sustainable supply of antibiotics, AMR-relevant vaccines, new technologies, and diagnostics.

Support collaboration and sharing of relevant non-proprietary data with different stakeholders (e.g., academia, consortia, SMEs, public researchers, and industry) to help address key scientific and public health challenges.

The Faltering Antibiotic Pipeline

Antimicrobial resistance is rendering essential antibiotics increasingly ineffective, driving a major global health crisis. Without effective antibiotics, many modern medical procedures such as chemotherapy, organ transplants, caesarean sections, and chronic disease management would not be possible.

While new antibiotics are essential for treating resistant infections, the development pipeline continues to shrink. Building on the *Leaving the Lab* report, which highlighted the decline in scientific talent in antimicrobial R&D, the AMR Industry Alliance launched *The Faltering Antibiotic Pipeline*—an infographic underscoring the shortage of new antimicrobials in development. Together, these analysis reveal a dual challenge: significant barriers to antimicrobial R&D and a fundamentally broken market.



Only seven new antibiotics have been approved in the past five years, and success rates remain far lower than other therapies. Without policy initiatives to stabilize the fragile antibiotic ecosystem, we risk a return to a pre-antibiotic era.

An interactive digital version of the infographic will launch in early 2026.

KEY SURVEY FINDINGS

- 1 Antimicrobial products are 100x less likely to succeed than the average pharmaceutical product in development.
- 2 Only 7 new antibiotics were approved in the last five years. In the 1980s, 4-6 new antibiotics were approved per year.
- 3 Urgent policy initiatives are needed to stabilize the fragile antibiotic R&S ecosystem and encourage antimicrobial development.



AMR Industry Alliance's Global Engagement

In 2025, the AMR Industry Alliance continued to advance its role as a leading industry voice for the life sciences sector, facilitating ongoing international engagement and leadership through the Multi-Stakeholder Partnership Platform (MSPP), the World Health Organization (WHO) and Africa CDC. The Alliance also co-facilitated the Independent Scientific Panel and Gap Hearings through MSPP at the request of the Quadripartite Joint Secretariat on AMR (QJS).

Fourth Dialogue in the Wilton Park series

In February 2025, the AMR Industry Alliance and members participated in the Fourth Dialogue in the Wilton Park series titled “Reinvigorating the response to antimicrobial resistance (AMR): from aspiration to implementation.” The Dialogue focused on translating the outcomes of the 2024 UN High-Level Meeting on AMR into practical actions to advance the global response to AMR.

Discussions centered on removing barriers to access, improving availability in low- and middle-income countries, strengthening antimicrobial stewardship, and creating incentives to support the development of new antibiotics and diagnostics. Participants also explored opportunities to enhance global AMR governance through the Global Leaders Group on AMR, the AMR Multistakeholder Partnership Platform, and the independent panel for scientific evidence. The outcomes of the Dialogue are summarized in an Outcomes Statement, available [here](#).



AMR Industry Alliance and WHO

The World Health Organization reached out directly to the Alliance to request input on its target product profile (TPP) for diagnostic tests for serious bacterial infections in newborns and young infants, including neonatal sepsis.

Africa CDC Meeting – “Opening the Doors to Access: A Continental Call to Action”

The AMR Industry Alliance and members participated in the first Continental stakeholders Meeting on Access to Antimicrobials, Diagnostics, and Vaccines as Countermeasures to AMR, hosted by Africa CDC in Addis Ababa, Ethiopia.



This landmark convening brought together policymakers, regulators, researchers, manufacturers, and development partners to drive urgent action on AMR. Discussions focused on addressing the critical gaps undermining Africa’s ability to respond effectively to AMR, strengthening health security, and developing a unified roadmap aimed at expanding access to life-saving antimicrobials, diagnostics, and vaccines.

Africa bears the highest mortality rate from AMR globally, underscoring the urgency of coordinated action. Expanding access to antimicrobial products across the continent is a critical step toward achieving the goals of the 2024 High-Level Declaration on AMR.

Webinars

Medicines for Europe



Principles of Responsible Manufacturing of Antibiotics and the AMR Industry Alliance

GARDP



Cefiderocol Access Project: Where are we now?

AMRIA in the Press

The Alliance was featured in a European Bank for Reconstruction and Development (EBRD) [report](#), “EBRD Engagement in Global Efforts to Curb Antimicrobial Resistance (AMR),” which highlights the responsible manufacturing standard and BSI certification.



The Alliance was featured in the Innovation News Network’s [article](#) “Global innovation and collaboration in the fight against antimicrobial resistance.”

The updated Antibiotic Manufacturing Standard was [covered](#) by the Center for Infectious Disease Research and Policy (CIDRAP).



The Alliance was featured in the [article](#) “Advancing Green Pharmaceuticals: Sustainable Biomanufacturing Practices Across Asia Pacific,” by BioSpectrum Asia.

AMRIA in the Press

AMR Industry Alliance Secretariat Lead Melissa Gong Mitchell addressed the challenge of developing new antimicrobials and highlighted the Alliance's *Leaving the Lab [report](#)* in an article by Open Access Government.



The Alliance was featured in "A Personnel Problem: We Need More Antimicrobial Researchers, Infectious Disease Clinicians," a [video](#) by ContagionLive.

The Alliance was featured in Innovation News Network's [article](#) "The hidden threat of AMR in the environment," written by Steve Brooks, Chair of the Manufacturing working group.



Health Insight
A Mediaplanet Content Hub

The Alliance was featured in an [article](#) by Health Insight titled "Antimicrobial Resistance: A Growing Threat to Global Health," written by AMR Industry Alliance Secretariat Lead Melissa Gong Mitchell.



The Alliance is proud to partner with organizations across sectors, and we invite continued collaboration with governments, multi-lateral organizations, non-governmental organizations, academic institutions, and patient advocacy groups to help us bring about progress in the critical fight against AMR.

References

1. Wellcome Trust. (2024, Sept 16). New forecasts reveal that 39 million deaths will be directly attributable to bacterial antimicrobial resistance (AMR) between 2025-2050. <https://wellcome.org/news/new-forecasts-reveal-39-million-deaths-will-be-directly-attributable-bacterial-antimicrobial>
2. GBD 2021 Antimicrobial Resistance Collaborators (2024, Sept 28). Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. *The Lancet*, 404(10459), 1199-1226. [https://doi.org/10.1016/S0140-6736\(24\)01867-1](https://doi.org/10.1016/S0140-6736(24)01867-1)
3. McDonnell A, Countryman A., Laurence T., et al. (2024, Sept.) Forecasting the Fallout from AMR: Economic Impact of Antimicrobial Resistance in Humans. World Organisation for Animal Health and World Bank. <https://doi.org/10.20506/ecoAMR.3539>
4. Ibid.
5. Knowles, R., Sharland, M., Hsia, Y., Magrini, N., Moja, L., Siyam, A., & Tayler, E. (2020). Measuring antibiotic availability and use in 20 low- and middle-income countries. *Bulletin of the World Health Organization*, 98(3), 177–187C. <https://doi.org/10.2471/BLT.19.241349>
6. Honda, H., Murakami, S., Tokuda, Y., Tagashira, Y., & Takamatsu, A. (2020). Critical National Shortage of Cefazolin in Japan: Management Strategies. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 71(7), 1783–1789. <https://doi.org/10.1093/cid/ciaa216>
7. Outterson, K., Orubu, E. S. F., Rex, J., Årdal, C., & Zaman, M. H. (2022). Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 74(7), 1183–1190. <https://doi.org/10.1093/cid/ciab612>
8. Levy-Hara, G., Amábile-Cuevas, C. F., Gould, I., Hutchinson, J., Abbo, L., Saxynger, L., Vlieghe, E., Cardoso, F. L., Methar, S., Kanj, S., Ohmagari, N., Harbarth, S., & International Society of Chemotherapy Antimicrobial Stewardship Working Group (2011). "Ten Commandments" for the Appropriate use of Antibiotics by the Practicing Physician in an Outpatient Setting. *Frontiers in microbiology*, 2, 230. <https://doi.org/10.3389/fmicb.2011.00230>
9. Thomas, D., CFA, & Wessel, C. (2022). The State of Innovation in Antibacterial Therapeutics. *BIO INDUSTRY ANALYSIS*. <https://www.bio.org/sites/default/files/2022-02/The-State-of-Innovation-in-Antibacterial-Therapeutics.pdf>
10. Ibid.

ABOUT THE AMR INDUSTRY ALLIANCE

The AMR Industry Alliance is one of the largest private-sector coalitions established to provide sustainable solutions to curb antimicrobial resistance. The Alliance, comprised of 77 biotechnology, diagnostics, generics, and research-based pharmaceutical companies and 10 trade associations, facilitates collaboration, reports on the industry's contribution to the fight against AMR, and engages with external stakeholders. The Alliance seeks to contribute sustainable solutions to curb antimicrobial resistance by creating broad industry momentum and facilitating collaboration between the public and private sectors.

amrindustryalliance.org



Chemin des Mines 9, P.O. Box 195
1211 Geneva 20, GE 1211 Switzerland
Tel: +41 22 338 32 00 | Fax: +41 22 338 32 99
info@amrindustryalliance.org
Publication Date: 2024